Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 62 of 114

  1. MK-2870-021

    Merck Sharp and Dohme

    Ovarian cancer

    phase 3 small molecule active

    1 trial

  2. MK-2870-022

    Merck Sharp and Dohme

    Ovarian cancer recurrent

    phase 3 small molecule active

    1 trial

  3. MK-2870-023

    Merck Sharp and Dohme

    Participants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  4. MK-2870-031

    Merck Sharp and Dohme

    Locally advanced/metastatic urothelial carcinoma

    phase 3 small molecule active

    1 trial

  5. MK-2870-032

    Merck Sharp and Dohme

    Breast Cancer: triple negative breast cancer (TNBC) and hormone receptor (HR)-low positive/HER2 negative breast cancer

    phase 3 small molecule active

    1 trial

  6. MK-2870-033

    Merck Sharp and Dohme

    pMMR endometrial carcinoma

    phase 3 small molecule active

    1 trial

  7. MK-2870-036

    Merck Sharp and Dohme

    Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1

    phase 3 small molecule active

    1 trial

  8. MK-3475-091

    Merck Sharp and Dohme

    Stage IB (T ≥ 4 cm), II and IIIA NSCLC

    phase 3 small molecule active

    1 trial

  9. MK-3475-426

    Merck Sharp and Dohme

    Metastatic renal cell carcinoma

    phase 3 small molecule active

    1 trial

  10. MK-3475-585

    Merck Sharp and Dohme

    Gastric and gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  11. MK-3475-669

    Incyte

    Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies

    phase 3 small molecule active

    1 trial

  12. MK-3475-679

    Incyte

    Locally advanced/metastatic renal cell carcinoma

    phase 3 small molecule active

    1 trial

  13. MK-3475-811

    Merck Sharp and Dohme

    Gastric or gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  14. MK-3475-866

    Merck Sharp and Dohme

    Cis-eligible Muscle-invasive bladder cancer.

    phase 3 small molecule active

    1 trial

  15. MK-3475-905

    Merck Sharp and Dohme

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  16. MK-3475-966

    Merck Sharp and Dohme

    Biliary Tract Carcinoma

    phase 3 small molecule active

    1 trial

  17. MK-3475-991

    Merck Sharp and Dohme

    Metastatic hormone sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  18. MK-3475-A18

    Merck Sharp and Dohme

    Locally Advanced Cervical Cancer

    phase 3 small molecule active

    1 trial

  19. MK-3475-A86

    Merck Sharp and Dohme

    Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).

    phase 3 small molecule active

    1 trial

  20. MK-3475-C93

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  21. MK-3475A-F84

    Merck Sharp and Dohme

    Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS ≥50%

    phase 3 small molecule active

    1 trial

  22. MK-3543-006

    Merck Sharp and Dohme

    Essential Thrombocythemia patients who have an inadequate response to or are intolerant of hydroxyurea

    phase 3 small molecule active

    1 trial

  23. MK-3543-007

    Merck Sharp and Dohme

    Essential thrombocythemia

    phase 3 small molecule active

    1 trial

  24. MK-3543-017

    Merck Sharp and Dohme

    Myeloproliferative Neoplasms (Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis)

    phase 3 small molecule active

    1 trial

  25. MK-4280A-007

    Merck Sharp and Dohme

    Colorectal Cancer

    phase 3 small molecule active

    1 trial

  26. MK-4482-023

    Merck Sharp and Dohme

    SARS-CoV-2 (COVID-19) infection

    phase 3 small molecule active

    1 trial

  27. MK-5684-003

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  28. MK-5684-004

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  29. MK-5684-015

    Merck Sharp and Dohme

    Breast cancer, Ovarian cancer, Endometrial cancer

    phase 3 small molecule active

    1 trial

  30. MK-6194, Placebo for MK-6194

    Merck Sharp and Dohme

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  31. MK-6482-011

    Merck Sharp and Dohme

    Advanced RCC with clear cell component

    phase 3 small molecule active

    1 trial

  32. MK-6482-033

    Merck Sharp and Dohme

    Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  33. MK-6482-034

    Merck Sharp and Dohme

    Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  34. MK-6482-043

    Merck Sharp and Dohme

    Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2α related Genetic Alterations

    phase 3 small molecule active

    1 trial

  35. MK-7240-001

    Merck Sharp and Dohme

    Ulcerative colitis

    phase 3 small molecule active

    1 trial

  36. MK-7240-008

    Merck Sharp and Dohme

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  37. MK-7240-008 study 2

    Merck Sharp and Dohme

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  38. MK-7339-006

    Merck Sharp and Dohme

    Stage IV lung cancer condition

    phase 3 small molecule active

    1 trial

  39. MK-7339-008

    Merck Sharp and Dohme

    Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  40. MK-7339-012

    Merck Sharp and Dohme

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  41. MK-7339-013

    Merck Sharp and Dohme

    Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease.

    phase 3 small molecule active

    1 trial

  42. MK-7962-038

    Merck Sharp and Dohme

    ​​Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  43. MK-8527

    Merck KGaA, Darmstadt, Germany

    Human Immunodeficiency Virus (HIV)

    phase 3 small molecule active

    1 trial

  44. MK-8527-011

    Merck Sharp and Dohme

    HIV-1 prevention

    phase 3 small molecule active

    1 trial

  45. MK-8591A

    Merck Sharp and Dohme

    HIV infection

    phase 3 small molecule active

    1 trial

  46. MK-8591A-053

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  47. MK-8591B-062

    Merck Sharp and Dohme

    HIV

    phase 3 small molecule active

    1 trial

  48. MK2870-004

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.